ClinicalTrials.gg
TerminatedNCT04615845Updated Sep 21, 2026

A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC

A Phase 1 interventional study of Cellgram-DC-PC in Metastatic Castration Resistant Prostate Cancer, sponsored by Pharmicell Co., Ltd.. Terminated at 1 site in South Korea. Open to male participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Pharmicell Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Difficulties in patient recruitment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
19 Years to 79 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 198 studies in Prostatic Neoplasms with a site in Korea, Republic of — 48 open to participants now, 81 under way, 37 of them phase 3. Prostatic Neoplasms · Korea, Republic of.

Enrollment
165th of 165
3 · median 208
Started
2021
with 15 others
Phase 1
17 of 198
7 open now
Registered
119th of 198
by date

Among the 198 studies in Prostatic Neoplasms with a site in Korea, Republic of, this one is the 165th largest by enrollment of the 165 interventional ones that give a count, is one of 16 that started in 2021, is one of 17 in phase 1, and was the 119th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

48 of the 198 studies in Prostatic Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 19 Years to 79 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Prostatic Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this clinical trial was to evaluate the safety of Cellgram-DC-PC, an autologous dendritic cell-based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Read the detailed description

Cellgram-DC-PC is an autologous dendritic cell-based cancer immunotherapy developed for patients with metastatic castration-resistant prostate cancer (mCRPC). This was a Phase 1, single-center, open-label clinical trial designed to characterize the safety profile of Cellgram-DC-PC following administration in patients with mCRPC.

03

Conditions studied

  • Metastatic Castration Resistant Prostate Cancer

Browse trials for

Keywords

  • Metastatic Castration-Resistant Prostate Cancer
  • mCRPC
  • Autologous Dendritic Cell
  • Cancer Immunotherapy
  • Cellgram-DC-PC
  • Prostate Cancer
04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 19 and under 80 years
  2. confirmed prostate adenocarcinoma
  3. Patients with stage M1a or M1b with extrapelvic lymph nodes and bone
  4. Patients diagnosed with castration-resistant prostate cancer after failure of male hormone deprivation therapy (Castrate levels of testosterone \<50 ng/dL) and If either a or b is satisfied:

    1. Biochemical progression: Prostate Specific Antigen (PSA) increases three times in a row at 1 week intervals, two 50% increases compared to the lowest point, PSA> 2ng/mL, or
    2. Radiological progression: appearance of new lesions; 2 or more new lesions on the bone scan
  5. Asymptomatic or mild patients after previous treatment

    1. Patients who have not used narcotic analgesics within 21 days prior to enrollment
    2. Patients with an average weekly pain of less than 4 on the Visual Analogue Scale(VAS) (out of 10)
  6. Combination of Luteinizing hormone-releasing hormone(LHRH) analogs (leuprolide (Lupron, Viadur, Eligard) and goserelin (Zoladex, etc.) for the inhibition of gonadotropin is allowed
  7. Whole body performance status: European Cooperative Oncology Group() 0\~1
  8. Patients whose is at least 6 months or longer
  9. ≥ 8.0g/dL, (ANC) ≥ 1,500/mm3, ≥ 100,000/mm3
  10. Serum Creatinine ≤ 2.0 x (ULN) or Calculated > 30mL/min
  11. Total ≤ 1.5 x ULN or Direct bilirubin ≤ ULN, Aminotransferase ()/Alanine aminotransferase(ALT) \<2.5 x ULN
  12. Patients who did not receive surgery, radiation therapy, or immunotherapy within the last 6 weeks and recovered from side effects
  13. Patients who agreed to use medically recognized methods during the clinical trial participation period
  14. Patients who voluntarily participated in clinical trials and signed the Informed Contents Form (ICF)

Exclusion criteria

Exclusion Criteria:

  1. Patients who have a local recurrence and are scheduled for local treatment.
  2. Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years
  3. Patients with visceral (metastases to the lungs, liver, adrenal glands, peritoneum, brain, etc.)
  4. Patients who previously received anti-tumor immunotherapy (anti-PD1, anti-PDL1 or anti-PDL2, etc.) or participated in immunotherapy-related clinical trials
  5. Patients with active diseases requiring systemic treatment (e.g., immunosuppressants such as cyclosporin A or azathioprine or for disease control)
  6. Patients with medical conditions requiring continuous or intermittent administration of systemic steroids or immunosuppressants
  7. Patients who received blood products (limited to whole blood products) within 4 weeks of screening criteria, or patients who received colony stimulating factors (Colony Stimulating Factor or recombinant Erythropoietin)
  8. Patients with a history of organ or hematopoietic stem cell transplantation
  9. Patients with acute or chronic infections requiring systemic treatment
  10. Patients known to be infected with (HIV)/serum positive
  11. Patients with active hepatitis A, B or C
  12. Patients with untreated syphilis (Fluorescent Treponemal Antibody Absorption Test (FTA-ABS) Immunoglobulin M positive patients)
  13. Patients expected to require therapeutic biotherapy or immunotherapy
  14. Patients who received (e.g. measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), oral typhoid vaccine, Flu-Mist, etc.) within 30 days
  15. Patients with a history of anaphylaxis to gentamicin
  16. Others, if the person in charge of the study determines that it is not suitable for the clinical trial
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Cellgram-DC-PC

    Participants received Cellgram-DC-PC by subcutaneous injection near the inguinal lymph nodes.

    Biological: Cellgram-DC-PC

Interventions

  • BiologicalCellgram-DC-PC

    Patients received three subcutaneous injections of Cellgram-DC-PC (autologous dendritic cells) near the inguinal lymph nodes at Weeks 0, 2, and 4.

    Also known as: Autologous dendritic cell anti-cancer immune cell therapy for prostate cancer treatment

06

What researchers measure

Primary outcomes

  1. Adverse Event

    Adverse events (AEs) were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: From informed consent to the end of treatment at Week 28.

Secondary outcomes

  1. Immune Response

    Tumor antigen-specific immune responses were evaluated by measuring changes in serum IFN-γ and IL-12 levels and antigen-specific T-cell responses following administration of the investigational product.

    Time frame: At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.

  2. Change in Prostate-Specific Antigen (PSA)

    Exploratory efficacy was evaluated by measuring changes in prostate-specific antigen (PSA) levels from pre-treatment (Week 0) to post-treatment assessment.

    Time frame: At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.

07

Study locations

1 site
  • Asan medical center
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made available to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Feb 2022, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2020
First posted
Nov 4, 2020
StartActual
Jul 5, 2021
Primary completionActual
Feb 15, 2022
CompletionActual
Jun 30, 2022
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04615845
Lead sponsor
Pharmicell Co., Ltd.
Responsible party
Sponsor
First posted
Nov 4, 2020
Start date
Jul 5, 2021
Primary completion
Feb 15, 2022
Completion
Jun 30, 2022
Last update
Sep 21, 2026

Study contacts

BUMJIN LIM, Ph.D
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion